We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Aeglea Biotherapeutics Inc
16 own
29 watching
Current Price
$0.49
$0.01
(2.71%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
30.32M
52-Week High
4.54
52-Week Low
0.34
Average Volume
0.08M
Dividend Yield
--
P/E Ratio
--
Market Capitalization30.32M52-Week High4.5452-Week Low0.34Average Volume0.08MDividend Yield--P/E Ratio--What does the Aeglea Biotherapeutics Inc do?
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company s lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Read More
How much money does Aeglea Biotherapeutics Inc make?
News & Events about Aeglea Biotherapeutics Inc.
Zolmax
16days ago
StockNews.com began coverage on shares of Aeglea BioTherapeutics (NASDAQ:AGLE Get Rating) in a research note released on Monday morning. The firm issued a hold rating on the biotechnology companys stock. AGLE has been the topic of several other research reports. Piper Sandler increased their target ...
PR Newswire
20days ago
Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency PR Newswire AUSTIN, Texas, Jan. 6, 2023 Streamlining of organization to focus on near-term deliverables...
Zolmax
2 months ago
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE Get Rating) saw a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 611,000 shares, an increase of 17.8% from the October 15th total of 518,700 shares. Based on an average daily trading ...
Ticker Report
3 months ago
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE Get Rating) was the target of a large decline in short interest in the month of October. As of October 15th, there was short interest totalling 518,700 shares, a decline of 24.1% from the September 30th total of 683,100 shares. Based on an average ...
PR Newswire
5 months ago
Aeglea BioTherapeutics Announces Leadership Transition and Corporate Restructuring Aeglea BioTherapeutics Announces Leadership Transition and Corporate Restructuring PR Newswire AUSTIN, Texas, Aug. 24, 2022 PrioritizingResources and Focus on AGLE-177 and the Completion of the Ongoing Phase 1/2...
Frequently Asked Questions
Frequently Asked Questions
What is Aeglea Biotherapeutics Inc share price today?
Can Indians buy Aeglea Biotherapeutics Inc shares?
How can I buy Aeglea Biotherapeutics Inc shares from India?
Can Fractional shares of Aeglea Biotherapeutics Inc be purchased?
What are the documents required to start investing in Aeglea Biotherapeutics Inc stocks?
What is today’s traded volume of Aeglea Biotherapeutics Inc?
What is today’s market capitalisation of Aeglea Biotherapeutics Inc?
What is the 52-Week High and Low Range of Aeglea Biotherapeutics Inc?
What percentage is Aeglea Biotherapeutics Inc down from its 52-Week High?
What percentage is Aeglea Biotherapeutics Inc up from its 52-Week Low?
Current Price
$0.49
$0.01
(2.71%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.